Insider Transactions in Q1 2024 at Immuno Gen, Inc. (IMGN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2024
|
Richard John Wallace Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Feb 12
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
584,397
-100.0%
|
-
|
|
Feb 12
2024
|
Helen M. Thackray Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,074
-100.0%
|
-
|
|
Feb 12
2024
|
Dean J Mitchell Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,000
-100.0%
|
-
|
|
Feb 12
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,039
-100.0%
|
-
|
|
Feb 12
2024
|
Stuart A Arbuckle Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,381
-100.0%
|
-
|
|
Feb 12
2024
|
Mark Alan Goldberg Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
60,720
-100.0%
|
-
|
|
Feb 12
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,723
-100.0%
|
-
|
|
Feb 12
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
73,274
-100.0%
|
-
|
|
Feb 12
2024
|
Michael Vasconcelles EVP R&D & MEDICAL AFFAIRS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,327
-100.0%
|
-
|
|
Feb 12
2024
|
Daniel Char SVP & CHIEF LEGAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,000
-100.0%
|
-
|
|
Feb 05
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,583
-5.89%
|
$132,907
$29.3 P/Share
|
|
Feb 05
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Open market or private sale
|
Direct |
2,631
-15.16%
|
$76,299
$29.3 P/Share
|
|
Feb 05
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
20,107
-3.33%
|
$583,103
$29.28 P/Share
|
|
Feb 05
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
12,027
-36.37%
|
$348,783
$29.3 P/Share
|
|
Feb 02
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,350
+15.56%
|
-
|
|
Feb 02
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,435
+32.71%
|
-
|
|
Feb 02
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,234
+7.81%
|
-
|
|
Feb 02
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
29,640
+47.27%
|
-
|
|
Jan 16
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
187,667
-98.21%
|
$5,442,343
$29.64 P/Share
|
|
Jan 16
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
187,667
+30.76%
|
$938,335
$5.28 P/Share
|